JP2018521086A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521086A5
JP2018521086A5 JP2018503496A JP2018503496A JP2018521086A5 JP 2018521086 A5 JP2018521086 A5 JP 2018521086A5 JP 2018503496 A JP2018503496 A JP 2018503496A JP 2018503496 A JP2018503496 A JP 2018503496A JP 2018521086 A5 JP2018521086 A5 JP 2018521086A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
dextran sulfate
use according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018503496A
Other languages
English (en)
Japanese (ja)
Other versions
JP6837679B2 (ja
JP2018521086A (ja
Filing date
Publication date
Priority claimed from SE1551050A external-priority patent/SE539575C2/en
Application filed filed Critical
Publication of JP2018521086A publication Critical patent/JP2018521086A/ja
Publication of JP2018521086A5 publication Critical patent/JP2018521086A5/ja
Application granted granted Critical
Publication of JP6837679B2 publication Critical patent/JP6837679B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018503496A 2015-07-30 2016-07-15 硫酸デキストランの新しい使用 Active JP6837679B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1551050-6 2015-07-30
SE1551050A SE539575C2 (en) 2015-07-30 2015-07-30 Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
PCT/SE2016/050720 WO2017018922A1 (en) 2015-07-30 2016-07-15 New use of dextran sulfate

Publications (3)

Publication Number Publication Date
JP2018521086A JP2018521086A (ja) 2018-08-02
JP2018521086A5 true JP2018521086A5 (https=) 2018-09-13
JP6837679B2 JP6837679B2 (ja) 2021-03-03

Family

ID=57884849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503496A Active JP6837679B2 (ja) 2015-07-30 2016-07-15 硫酸デキストランの新しい使用

Country Status (11)

Country Link
US (1) US10478451B2 (https=)
EP (1) EP3328395B1 (https=)
JP (1) JP6837679B2 (https=)
CN (2) CN114712385A (https=)
BR (1) BR112018001942A2 (https=)
DK (1) DK3328395T3 (https=)
EA (1) EA034313B1 (https=)
ES (1) ES2882115T3 (https=)
HK (1) HK1246640A1 (https=)
SE (1) SE539575C2 (https=)
WO (1) WO2017018922A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212708A1 (en) * 2017-05-17 2018-11-22 Tx Medic Ab Treatment of glaucoma
ES2777836T3 (es) * 2017-05-17 2020-08-06 Tx Medic Ab Tratamiento del glaucoma
AU2018329430B2 (en) 2017-09-08 2024-05-02 Tx Medic Ab New use of dextran sulfate
US20190275212A1 (en) * 2018-03-09 2019-09-12 Carmeda Ab Processes for immobilising biological entities
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation
SE544447C2 (en) * 2020-09-29 2022-05-31 Tx Medic Ab Treatment of fatty liver diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
US20040224922A1 (en) 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
SE525461C3 (sv) * 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
WO2007028053A2 (en) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
WO2007075388A2 (en) * 2005-12-15 2007-07-05 X-Cell Medical Incorporated Methods of locally treating and preventing cardiac disorders
WO2008134430A1 (en) * 2007-04-24 2008-11-06 Novelmed Therapeutics Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
WO2011091167A2 (en) * 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
WO2013057167A1 (en) * 2011-10-18 2013-04-25 Csl Behring Gmbh Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
CN102973593A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗肝纤维化药物中的应用
JP6557683B2 (ja) * 2014-06-12 2019-08-07 ティーエックス メディック エービー 被験体において血管新生を誘導するための10000da未満の平均分子量を有するデキストラン硫酸の使用
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject

Similar Documents

Publication Publication Date Title
JP2018521086A5 (https=)
JP2015057436A5 (https=)
WO2012012347A3 (en) Methods of intravenous administration of glyburide and other drugs
JP2011528333A5 (https=)
JP2016106150A5 (https=)
JP2016516016A5 (https=)
JP2011225596A5 (https=)
JP2016517421A5 (https=)
JP2014077003A5 (https=)
JP2015515475A5 (https=)
JP2010518122A5 (https=)
JP2015518818A5 (https=)
WO2007087241A3 (en) Treatment of ischemic disease using thrombopoietin
JP2015502389A5 (https=)
JP2020524689A5 (https=)
JP2015517994A5 (https=)
JP2016517401A5 (https=)
JP2019529570A5 (https=)
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
ES2924728T3 (es) Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
JP2012525358A5 (https=)
JP2016512247A5 (https=)
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
JP2014504636A5 (https=)